| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 17 | -32* | 26 | 160 |
| Research and development (includes and (5) from a related party) | 122 | 56* | 141 | 139 |
| Impairment of long-lived assets (see note 14, leases) | NaN | 0* | 0 | 0 |
| General and administrative (includes and from a related party) | 29 | 26* | 27 | 29 |
| Total operating expenses | 151 | 82* | 168 | 168 |
| Loss from operations | -134 | -114 | -142 | -8 |
| Interest and other income, net | 9 | 10 | 10 | 10 |
| Interest expense | 3 | 2 | 3 | 2 |
| Total non-operating income, net | 6 | 8 | 7 | 8 |
| Loss before income taxes | -128 | -106 | -135 | 0 |
| Federal statutory income taxes | NaN | 19* | NaN | NaN |
| State taxes, net of federal benefit | NaN | 0* | NaN | NaN |
| Domestic research and development credits | NaN | -4* | NaN | NaN |
| Equity investment | NaN | 3* | NaN | NaN |
| Stock based compensation | NaN | -1* | NaN | NaN |
| Other items | NaN | -1* | NaN | NaN |
| Change in valuation allowance | NaN | -23* | NaN | NaN |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net loss | -128 | -106 | -135 | 0 |
| Basic EPS | -1.02 | -0.894 | -1.27 | 0 |
| Diluted EPS | -1.02 | -0.897 | -1.27 | 0 |
| Basic Average Shares | 125,400,000 | 118,600,000 | 106,500,000 | 106,100,000 |
| Diluted Average Shares | 125,400,000 | 118,200,000 | 106,500,000 | 106,500,000 |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)